Mersana Therapeutics (MRSN) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Mersana Therapeutics in October 2026.
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
Mersana Therapeutics (MRSN) Stock Forecast
Analyst price target, next 12 months
$33.20
+20.6% vs today's $27.52
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Mersana Therapeutics have a consensus 12-month target of $33.20, above the current price of $27.52.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 3 Dec 2025.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Mersana Therapeutics' stock with a target price of $33.20, indicating potential growth.
Financial Health
Mersana Therapeutics is generating modest revenue and cash flow, indicating a stable financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
